Skip to main content

Table 1 Patient characteristics

From: Decreased hormonal sensitivity after childbirth rather than the tumor size influences the prognosis of very young breast cancer patients

Factors Case (younger than 30) Control (elder counterpart) Chi square test PABC 47 cases
Cases (%) Cases (%) P value Cases (%)
Calendar year of surgery
 1986–1995 40 (50.0%) 40 (50.0%) >0.9999 25 (53.2%)
 1996–2002 40 (50.0%) 40 (50.0%)   22 (46.8%)
Age at surgery, years old
 <35 80 (100.0%) 1 (1.3%) <0.0001 20 (42.6%)
 ≥35 0 (0.0%) 79 (98.8%)   27 (57.4%)
Family history of breast cancer
 None 69 (86.3%) 69 (86.3%) >0.9999 40 (85.1%)
 Positive 11 (13.8%) 11 (13.8%)   7 (14.9%)
Years from the last childbirth (YFLC)
 Nulliparous 68 (85.0%) 16 (20.0%) <0.0001 4 (8.5%)
 Recent (<8) 12 (15.0%) 8 (10.0%)   43 (91.5%)
 Past (≥8) 0 (0.0%) 56 (70.0%)   0 (0.0%)
Tumor size, cm (Pathological)
 ≤2 20 (25.0%) 23 (28.8%) 0.1826 13 (27.7%)
 2.1–5 28 (35.0%) 42 (52.5%)   21 (44.7%)
 >5 11 (13.8%) 6 (7.5%)   5 (10.6%)
The number of metastatic lymph nodes
 None 40 (50.0%) 38 (47.5%) 0.3553 14 (29.8%)
 1–3 24 (30.0%) 23 (28.8%)   15 (31.9%)
 4–9 6 (7.5%) 13 (16.3%)   11 (23.4%)
 10– 9 (11.3%) 6 (7.5%)   7 (14.9%)
Histological type
 Papillotubular carcinoma 18 (22.5%) 24 (30.0%) 0.1003 9 (19.1%)
 Sollid-tubular carcinoma 28 (35.0%) 16 (20.0%)   20 (42.6%)
 Scirrhous carcinoma 29 (36.3%) 27 (33.8%)   13 (27.7%)
 Special types 4 (5.0%) 10 (12.5%)   5 (10.6%)
 Unilateral double cancer 1 (1.3%) 3 (3.8%)   0 (0.0%)
Extent of tumor invasion (histological)
 Localized within mammary gland 29 (36.3%) 23 (28.8%) 0.4486 22 (46.8%)
 Invading the extramammary fat tissue 47 (58.8%) 50 (62.5%)   21 (44.7%)
 Invading the skin and/or muscle 4 (5.0%) 7 (8.8%)   4 (8.5%)
Lymphovascular invasion
 Absent 45 (56.3%) 53(66.3%) 0.2559 24 (51.1%)
 Present 35 (43.8%) 27(33.8%)   23 (48.9%)
Estrogen receptor(EIA), fmol/mg
 <5 (negative) 31 (38.8%) 30 (37.5%) 0.2563 31 (66.0%)
 5–21 (weakly positive) 14 (17.5%) 18 (22.5%)   2 (4.3%)
 22– (strongly positive) 9 (11.3%) 19 (23.8%)   4 (8.5%)
 Not performed 26 (32.5%) 13 (16.3%)   10 (21.3%)
Progesterone receptor(EIA), fmol/mg
 <10 (negative) 23 (28.8%) 20 (25.0%) 0.1555 23 (48.9%)
 10–95 (Weakly positive) 15 (18.8%) 20 (25.0%)   9 (19.1%)
 96– (Strongly positive) 13 (16.3%) 27 (33.8%)   3 (6.4%)
 Not performed 29 (36.3%) 13 (16.3%)   12 (25.5%)
Type of breast surgery
 Breast conserving surgery (BCS) 27 (33.8%) 16 (20.0%) 0.0738 6 (12.8%)
 Mastectomy 53 (66.3%) 64 (80.0%)   41 (87.2%)
Chemotherapy
 None 24 (30.0%) 28 (35.0%) 0.3417 12 (25.5%)
 Others 5 (6.3%) 10 (12.5%)   8 (17.0%)
 CMF 33 (41.3%) 31 (38.8%)   14 (29.8%)
 Anthracycline 13 (16.3%) 8 (10.0%)   8 (17.0%)
 Anthracycline and Taxane 5 (6.3%) 2 (2.5%)   5 (10.6%)
Hormone therapy
 Ovarian function suppression ± others 11 (13.8%) 7 (8.8%) 0.0007 4 (8.5%)
 Selective estrogen receptor modulators 8 (10.0%) 28 (35.0%)   10 (21.3%)
 Others, none 61 (76.3%) 45 (56.3%)   33 (70.2%)
Radiation therapy (RT)
 Not performed 63 (78.8%) 68 (85.0%) 0.3149 42 (89.4%)
 Performed 17 (21.3%) 12 (15.0%)   5 (10.6%)